AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02557685 — intervention group
Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Translantation involves administering fecal material from a healthy donor to a sick patient, with relapsing C-difficile infection, to restore missing components of normal intestinal flora. Subjects will receive Fecal Microbiota Translantation via sigmoidoscopy.
Study NCT02813902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heliocare with Fernblock PLE technology
Description: 240 mg taken orally daily over the course of 1 year
Study NCT02813902 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: A pill that appears similar to the supplement
Study NCT02114762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon dilation of the Eustachian tube
Description: Insert a balloon into one Eaustachian tube and inflate it for up to one minute. The balloon is then removed.
Study NCT03563625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: Caudal block/bupivacaine 0.25%
Study NCT03563625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Local anesthetic wound infiltration/bupivacaine 0.25%
Study NCT03563625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine
Study NCT01159951 — intervention group
Intervention type: OTHER
Intervention: Epidemiologic Surveillance System of the Ministry of Health of Panama
Description: Systematic review of the databases of epidemiologic surveillance system, Ministry of health, Panama
Study NCT04412525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy (27G gauge or larger needle)
Description: vitrectomy surgery for either floater removal or macular surgery, with or without combined cataract (phaco) surgery.
Study NCT00912210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein isolate
Description: Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50g/day (two 25 g doses taken at breakfast and afternoon snack mixed with food or beverage)
Study NCT00912210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin powder supplement
Description: Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50 g / day (two 25 g doses at breakfast and afternoon snack mixed with food or beverage)
Study NCT02229578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
Study NCT02229578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
Study NCT02034097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foretinib
Description: Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression
Study NCT02034097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Round white tablet containing either 25 mg, 100 mg, or 150 mg of erlotinib will be orally administered in a dose level of 150 mg OD until disease progression
Study NCT04830189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shoulder sling
Description: Patients were used shoulder slings
Study NCT04830189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: forearm sling
Description: Patients were used forearm slings
Study NCT04122209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIE-First
Description: Multiple exercise bout during the same day; HIIE first followed by continuous exercise
Study NCT04122209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous-First
Description: Multiple exercise bout during the same day; Continuous exercise first followed by HIIE
Study NCT01686867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Improved, ventilated cookstove
Description: An improved, ventilated cookstove incorporates the following key elements: burner openings customized to the size and shape of the cooking utensils; a flue designed to draw air into the fire box and pass it out through a chimney; a chimney, vented to the exterior, of adequate height to create a draft; an exterior port that has bidirectional openings to prevent the backflow of smoke and an access port for the chimney that permits cleaning.~The investigators piloted cookstoves prior to the trial and compared their ability to reduce indoor air pollution, the reliability between cookstoves of the same type, the functionality over time, preferences and cultural compatibility, and cost. The investigators selected the the Envirofit G-3300/3355, a modified Stovetec cookstove with a chimney and a locally-made improved, ventilated cookstove for use in the trial.
Study NCT03653767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Furniture
Description: The intervention will include adjustable school furniture.
Study NCT03959761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) nivolumab infusion
Description: Patients will be treated according to three dose-levels of nivolumab, starting 5 to 7 days after surgery + Hyperthermic Intraperitoneal Chemotherapy (HIPEC), through an Intraperitoneal (IP) catheter :~* Level 1 : 0.5 milligrams/kilogram (mg/kg) IP infusion, repeated every 2 weeks for 4 infusions~* Level 2 : 1 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~* Level 3 : 3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~* Level -1 : 0,3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions
Study NCT04648592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low salt diet plus sodium chloride supplements
Description: Patients will receive a low salt diet plus salt supplements.
Study NCT04648592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low salt diet plus placebo
Description: Patients will receive a low salt diet plus placebo.
Study NCT01615549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparsocopic cholecystectomy
Description: Perform laparsocopic cholecystectomy on a virtual reality devise
Study NCT01615549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparsocopic cholecystectomy
Description: Perform laparsocopic cholecystectomy on a virtual reality devise
Study NCT01485497 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3D endoscopic Fourier Domain OCT
Description: Evaluation of Obstructive Sleep Apnea
Study NCT02038712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fed Condition
Description: Subjects will consume a 600mL 600kcal liquid test meal
Study NCT02038712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasted condition
Description: Subjects will consume 600mL plain water.
Study NCT02038712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be collected at -15, 0, 10, 30, 60, 90, 120 min
Study NCT02038712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subjective appetite ratings
Description: Appetite ratings will be collected at -15, 0, 10, 30, 60, 90, 120 min.
Study NCT02038712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI scan
Description: Blood Oxygen Dependent (BOLD) signal response to pictures and words of food and non-food items will be measured using functional magnetic resonance imaging (fMRI).
Study NCT04190576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser Therapy
Description: Hydroxyapatite bone graft with collagen
Study NCT04190576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Hydroxyapatite bone graft with collagen
Study NCT05104255 — intervention group
Intervention type: PROCEDURE
Intervention: Spinal anesthesia
Description: Twins delivered under under spinal anesthesia
Study NCT05104255 — intervention group
Intervention type: PROCEDURE
Intervention: General anesthesia
Description: Twins delivered under general anesthesia
Study NCT03510455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: BGJ398, a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor will be orally administered over six 4-week cycles (4 weeks on drug continuously). After the initial dose, escalation/de- escalation of BGJ398 will be based on FGF- 23 blood levels and adjusted according to protocol procedures. The six cycles of BGJ398 will be followed by 3 months off the drug and an optional extension phase.
Study NCT01183039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: 20 sessions of training
Study NCT03090750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender Oil
Description: Lavender essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
Study NCT03090750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bergamot Oil
Description: Bergamot essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
Study NCT03090750 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Tap water applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
Study NCT03091816 — intervention group
Intervention type: DEVICE
Intervention: Computed Tomography Perfusion Imaging
Description: Undergo DPCT
Study NCT03091816 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03091816 — intervention group
Intervention type: RADIATION
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT02986945 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Resiliency App
Study NCT02986945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resiliency App
Study NCT01560845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cells infusion （ABMSCi） plus abdominal portal hypertension surgery
Description: Immediately after the harvest of ABMSC, the modified Sugiura procedure was performed for the patients who were assigned to the study group. The time of ABMSC separation and purification was 2.5-3 hours which had to be completed before the conclusion of portal hypertension surgery (3-3.5 hours). ABMSC was infused into proper hepatic artery through right gastric artery during the portal hypertension surgery
Study NCT01560845 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: open abdominal portal hypertension surgery
Description: the modified Sugiura procedure was performed for the patients
Study NCT04560374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: crochet octopus
Description: Delivering crochet octopus to the hands of the neonates
Study NCT00376415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lessertia Fructescens
Description: Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
Study NCT00376415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received an identical placebo capsule twice daily for 3 months.
Study NCT02838979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: First Intervention (14 days)
Description: Oral Glutamine or Maltodextrin for 2 weeks
Study NCT02838979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout (3 weeks)
Description: No study product is taken prior to beginning crossover
Study NCT02838979 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Second Intervention (14 days)
Description: Oral Glutamine or Maltodextrin for 2 weeks
Study NCT01108315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Report symptoms via web or phone-based system
Description: The participant reports their symptoms at least twice a week via the phone or web-based prototype system.
Study NCT00564616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video cell phone
Description: the voice group received voice CPR instruction via a voice-only cell phone, and the video group received interactive voice and video instruction via a video cell phone
Study NCT00564616 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: video cell phone
Description: the voice group received voice CPR instruction via a voice-only cell phone, and the video group received interactive voice and video instruction via a video cell phone
Study NCT03333161 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory monitoring
Description: We will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations).
Study NCT03333161 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiorespiratory monitoring
Description: We will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations).
Study NCT03653923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: Before the treatment, subjects will have one session of psychoeducation in which the rationale for the treatment is explained. In each therapy session subjects are exposed to 20 trials (each lasting 40s) of guided exposure by a psychotherapist. Further, 20 control trials of equal length are assessed in which subjects work with an earthworm. Each session lasts for approximately 90 minutes. During the therapy additional anxiety coping strategies (e.g., controlled breathing, attention refocusing, cognitive reappraisal) are trained.~Subjects of the waiting-list will be treated in the second study phase.
Study NCT01967069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFD01 Spray
Study NCT01967069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Spray
Study NCT02410005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcitriol
Study NCT02410005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Study NCT02410005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Study NCT02664597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADNEXMR Scoring System
Description: Patients will undergo a pelvic MR imaging (1.5T or 3T) as routinely performed, including morphological sequences (T2, T1 with and without fat suppression and T1 after dynamic gadolinium injection) and functional sequences (perfusion and diffusion-weighted sequences). Prospectively, a senior radiologist analyzes the different MR criteria to characterize adnexal masses. The reader will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score
Study NCT02664597 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard strategy
Description: In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.
Study NCT03674437 — intervention group
Intervention type: BEHAVIORAL
Intervention: Traditional Neurocognitive Assessments
Description: Traditional Neurocognitive Assessments given with pen and paper
Study NCT03674437 — intervention group
Intervention type: BEHAVIORAL
Intervention: Online Cognitive Battery (Cogsuite)
Description: Cognition (Cogsuite) for a battery that consists of seven measurements.
Study NCT01475461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: double-dummy placebo tablets administered once-daily for 84-days
Study NCT01475461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 - 3mg
Description: PF-04937319 3mg administered as tablets once-daily for 84-days
Study NCT01475461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 - 20mg
Description: PF-04937319 20mg administered as tablets once-daily for 84-days
Study NCT01475461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 - 50mg
Description: PF-04937319 50mg administered as tablets once-daily for 84-days
Study NCT01475461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 - 100mg
Description: PF-04937319 100mg administered as tablets once-daily for 84-days
Study NCT01475461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin - 100mg
Description: Sitagliptin 100mg administered as tablets once-daily for 84-days
Study NCT00609947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor Zotarolimus-Eluting Coronary Stent
Study NCT03539068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEB-ED+ Treatment Arm
Description: Veterans who screen positive on one or more mental health screens in WEB-ED will be RCT-eligible. RCT-consenters randomly assigned to the WEB-ED+ Treatment are will receive::~* eHealth interfaces tailored to Veterans' VA and MHV enrollment needs (links for electronic VA enrollment, MHV and MHV premium status enrollment).~* Shared decision making (SDM) interfaces: Patient Decision aids (PTSD, depression, alcohol abuse); SDM educational video; videos).~* Access to study staff available through a toll-free number to assist both Veterans and providers, including addressing questions, problem-solving about or assisting with stuck points (e.g. getting screening results to the provider).
Study NCT01721733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01721733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-743 15 mg/kg
Study NCT01721733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-743 5 mg/kg
Study NCT02511262 — intervention group
Intervention type: DEVICE
Intervention: illumigene® Mycoplasma Direct, illumipro-10
Description: DNA amplification assay
Study NCT03052660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral administration preoperatively
Study NCT03052660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral administration preoperatively
Study NCT00458952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultratrace Iobenguane (MIBG) I 131
Description: Phase I: Dose escalation protocol Phase II: Treatment schedule at therapeutic dose
Study NCT00003704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00003704 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03498703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine Pill
Description: Azathioprine increase pregnancy rate in cases with recurrent implantaion failure
Study NCT03498703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets
Study NCT04081077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
Study NCT04081077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
Study NCT04081077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
Study NCT04081077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
Study NCT04081077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
Study NCT01053767 — intervention group
Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Group B streptococcus (GBS) vaccine
Description: No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P2 study.